Platinum-based anticancer drugs, including cisplatin, carboplatin, oxaliplatin, nedaplatin,
and lobaplatin, are heavily applied in chemotherapy regimens. However, the intrinsic or …

Interstrand crosslinks (ICLs) are highly toxic DNA lesions that prevent transcription and
replication by inhibiting DNA strand separation. Agents that induce ICLs were one of the …

Tumours with specific DNA repair defects can be completely dependent on back-up DNA
repair pathways for their survival. This dependence can be exploited therapeutically to …

DNA interstrand cross-links (ICLs) are lesions caused by a variety of endogenous
metabolites, environmental exposures, and cancer chemotherapeutic agents that have two …

Although DNA double-strand breaks (DSBs) are substrates for homologous recombination
(HR) repair, it is becoming apparent that DNA lesions produced at replication forks, for …

In recent years, there have been multiple breakthroughs in our understanding of lung cancer
biology. Despite significant advances in molecular targeted therapies, DNA-damaging …

Interstrand cross-links (ICLs) block replication and transcription and thus are highly
cytotoxic. In higher eukaryotes, ICLs processing involves the Fanconi anemia (FA) pathway …

Bulky cisplatin lesions are repaired primarily by nucleotide excision repair (NER), in which
the structure specific endonuclease XPF–ERCC1 is a critical component. It is now known …

SLX4, the newly identified Fanconi anemia protein, FANCP, is implicated in repairing DNA
damage induced by DNA interstrand cross-linking (ICL) agents, topoisomerase I (TOP1) …

The efficient removal of replication and recombination intermediates is essential for the
maintenance of genome stability. Resolution of these potentially toxic structures requires the …